These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 16299847)

  • 1. One pill, two conditions.
    Kordella T
    Diabetes Forecast; 2005 Oct; 58(10):44. PubMed ID: 16299847
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecule of the month. Muraglitazar.
    Drug News Perspect; 2005 May; 18(4):284. PubMed ID: 16034485
    [No Abstract]   [Full Text] [Related]  

  • 3. Muraglitazar and the FDA: what constitutes drug safety?
    Liebson PR
    Prev Cardiol; 2006; 9(2):110-4. PubMed ID: 16603830
    [No Abstract]   [Full Text] [Related]  

  • 4. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meeting highlights. 65th annual scientific sessions of the American Diabetes Association, San Diego. Dual PPAR agonist improves glycemic control, lipids in type 2 diabetes.
    Geriatrics; 2005 Aug; 60(8):12. PubMed ID: 16104078
    [No Abstract]   [Full Text] [Related]  

  • 6. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
    Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N
    Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
    Heinzl S
    Med Monatsschr Pharm; 2006 Mar; 29(3):93-6. PubMed ID: 16550882
    [No Abstract]   [Full Text] [Related]  

  • 8. Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): good for sulfonylureas?
    Al-Ozairi E; Sibal L; Home P
    Diabetes Care; 2007 Jun; 30(6):1677-80. PubMed ID: 17351288
    [No Abstract]   [Full Text] [Related]  

  • 9. An overview of incretin clinical trials.
    Garber AJ; Spann SJ
    J Fam Pract; 2008 Sep; 57(9 Suppl):S10-8. PubMed ID: 18786339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy.
    Goldberg RB; Fonseca VA; Truitt KE; Jones MR
    Arch Intern Med; 2008 Jul; 168(14):1531-40. PubMed ID: 18663165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular disease and intensive glucose lowering in type 2 diabetes.
    Younis N; Soran H; Hassanein M
    QJM; 2009 Apr; 102(4):293-6. PubMed ID: 19147659
    [No Abstract]   [Full Text] [Related]  

  • 12. Achieving glycemic goals in type 2 diabetes.
    Bloomgarden ZT
    Diabetes Care; 2007 Jan; 30(1):174-80. PubMed ID: 17192357
    [No Abstract]   [Full Text] [Related]  

  • 13. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
    Fiévet C; Fruchart JC; Staels B
    Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. American Diabetes Association - 65th Scientific Sessions. PPAR agents.
    Erlich R
    IDrugs; 2005 Aug; 8(8):608-10. PubMed ID: 16044361
    [No Abstract]   [Full Text] [Related]  

  • 15. Incretin hormones poised for better control of diabetes.
    Morrow T
    Manag Care; 2005 Oct; 14(10):69-70. PubMed ID: 16277197
    [No Abstract]   [Full Text] [Related]  

  • 16. The ACCORD Trial and control of blood glucose level in type 2 diabetes mellitus: time to challenge conventional wisdom.
    Havas S
    Arch Intern Med; 2009 Jan; 169(2):150-4. PubMed ID: 19171811
    [No Abstract]   [Full Text] [Related]  

  • 17. Is it safe to combine PPAR agonists? A lesson from muraglitazar.
    Stulc T; Ceska R
    Med Hypotheses; 2006; 67(3):669. PubMed ID: 16762511
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevention of type 2 diabetes mellitus with antihypertensive drugs.
    Nilsson PM; Cifkova R; Kjeldsen SE; Mancia G
    Blood Press; 2006; 15(4):253-4. PubMed ID: 17078188
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevention of diabetes with rosiglitazone: Evidence of benefit or unexpected harm?
    Stulc T; Ceska R
    Med Hypotheses; 2008; 70(1):199-200. PubMed ID: 17855003
    [No Abstract]   [Full Text] [Related]  

  • 20. Fish oil supplements.
    Med Lett Drugs Ther; 2006 Jul; 48(1239):59-60. PubMed ID: 16841020
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.